Browse Data and Analysis

In September 2024, a National Assembly member submitted a draft revision of the Act on Transboundary Movements of Living Modified Organisms, commonly referred to as the LMO Act.

Kazakhstan has not announced any changes to its biotechnology policies. Major challenges like climate change, variable weather, monocropping wheat, and the reliance on Eurasian Economic Union (EAEU) member biotechnology regulations could be a future catalyst for Kazakhstan to develop its own biotechnology law.

Korea has not finalized the May 2021 revisions of its Living Modified Organism (LMO) Act, which defines Korea’s regulatory policies for products developed through innovative technologies including genome editing.

Kazakhstan has not announced any changes to its biotechnology policies. Major challenges like climate change, variable weather, monocropping wheat, and the reliance on Eurasian Economic Union (EAEU) member biotechnology regulations could be a future catalyst for Kazakhstan to develop its own biotechnology law.

In the past year, there have been no major changes in Kazakhstan’s biotechnology policies, although the government may be making plans to regulate and commercialize agricultural biotechnologies. For the time being, Kazakhstan continues to rely on Eurasian Economic Union (EAEU) regulations for guidance on biotechnology issues.

Korea is in the process of drafting a proposal to revise its existing Living Modified Organism (LMO) Act to cover products of innovative biotechnologies, including genome edited products.

In the past year, there have been no major changes in Kazakhstan’s biotechnology policy.

In April 2019, the Rural Development Administration (RDA) announced the creation of its Center to Commercialize New Breeding Technologies.

In the past year, there have been no major changes in Kazakhstan’s biotechnology policy.

This report provides minimal updates compared to the previous year’s report.

After 10 years under the Living Modified Organism (LMO) Act, Korea plans to improve and revise the LMO Act to address stakeholders’ concerns.

With the absence of any legislation regulating testing or approval of biotechnology events in Kazakhstan, leaders rely on Eurasian Economic Union (EAEU) regulations for guidance.